Immune Onc Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Palo Altocaliforniathe Company Focuses On Developing Innovative Therapies That Target Myeloid Cellswith An Emphasis On Immunology And Oncologytheir Goal Is To Create Treatments For Blood Cancerssolid Tumorsautoimmune Diseasesand Inflammatory Conditions By Modulating Specific Subsets Of Myeloid Cells Involved In Disease Processes The Company Specializes In Discovering And Developing Novel Biologic Treatmentsparticularly Myeloid Checkpoint Inhibitorsone Of Their Lead Candidatesio 202Is A First In Class Monoclonal Antibody Targeting Lilrb4 And Is Currently In A Phase 1 Clinical Trial For Advanced Acute Myeloid Leukemia And Chronic Myelomonocytic Leukemiaimmune Onc Has Received Orphan Drug Designation From The U Sfda For Io 202 In The Treatment Of Acute Myeloid Leukemia Immune Onc Collaborates With Prominent Academic Institutions And Is Supported By Experienced Investors To Further Its Mission Of Developing Innovative Immunotherapiesrecentlythe Company Secured $73 Million In Financing To Advance Its Portfolio In Blood Cancers And Solid Tumors
No conferences found for this company.
| Company Name | Immune Onc Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
